Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion Inc (BMEA)
:BMEA
BMEA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.25 - $19.35
Previous CloseN/A
Volume309.16K
Average Volume (3M)540.35K
Market Cap
$132.27M
Enterprise Value$287.44M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Mar 03, 2025EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding36,238,686
10 Day Avg. Volume468,536
30 Day Avg. Volume540,345
Standard Deviation0.38
R-Squared0.00195
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.42
Enterprise Value/Ebitda-1.92
Forecast
1Y Price Target
$25.71Price Target Upside643.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Biomea Fusion News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive topline results from the Phase 2 COVALENT-111 clinical trial evaluating icovamenib in patients with T2D were announced.
Product DevelopmentBiomea introduced BMF-650 as a novel, oral small-molecule GLP-1 RA candidate for diabetes and obesity.
Therapeutic BenefitsIcovamenib amplified all the key benefits of GLP-1-based therapies, including improved glycemic and body weight control.
Bears Say
Financing ConcernsThe weak share reaction and anticipation of BMEA trading range bound is influenced by the company's present financing overhang.
Market SkepticismThere is investor skepticism on the mechanism of action and the potential for sustained activity with additional treatment in the commercial setting.
Mechanism UncertaintyThe 26-week COVALENT-111 dose expansion results do little to advance the understanding of icovamenib’s mechanism of action on glucose homeostasis.
---
Ownership Overview
17.81% Insiders
14.95% Mutual Funds
21.50% Other Institutional Investors
37.77% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion Inc’s price range in the past 12 months?
Biomea Fusion Inc lowest stock price was $3.25 and its highest was $19.35 in the past 12 months.
What is Biomea Fusion Inc’s market cap?
Biomea Fusion Inc’s market cap is $132.27M.
When is Biomea Fusion Inc’s upcoming earnings report date?
Biomea Fusion Inc’s upcoming earnings report date is Mar 03, 2025 which is in 9 days.
How were Biomea Fusion Inc’s earnings last quarter?
Biomea Fusion Inc released its earnings results on Oct 29, 2024. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.944 by $0.034.
Is Biomea Fusion Inc overvalued?
According to Wall Street analysts Biomea Fusion Inc’s price is currently Undervalued.
Does Biomea Fusion Inc pay dividends?
Biomea Fusion Inc does not currently pay dividends.
What is Biomea Fusion Inc’s EPS estimate?
Biomea Fusion Inc’s EPS estimate is -0.91.
How many shares outstanding does Biomea Fusion Inc have?
Biomea Fusion Inc has 36,238,686 shares outstanding.
What happened to Biomea Fusion Inc’s price movement after its last earnings report?
Biomea Fusion Inc reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.944. Following the earnings report the stock price went down -14.262%.
Which hedge fund is a major shareholder of Biomea Fusion Inc?
Currently, no hedge funds are holding shares in BMEA
---
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.71 (643.06% Upside)
$25.71 (643.06% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 575.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.42%
12-Months-Change
Fundamentals
Return on Equity
-104.51%
Trailing 12-Months
Asset Growth
-50.94%
Trailing 12-Months
Company Description
Biomea Fusion Inc
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
---
BMEA Stock 12 Month Forecast
Average Price Target
$25.71
▲(643.06% Upside)
Technical Analysis
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-3.80%
reiterated a buy rating 4 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -3.80% per trade.
---